Osteologix, Inc. (OTCBB:OLGX), a bio-pharmaceutical company announced today that the company will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the United States and the rest of the world markets. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis.
”We believe that NB S101 will bring a safe and effective new alternative therapy for the millions of patients with osteoporosis. Our product can be manufactured and commercialized in a way that should also appeal to the cost conscious patients, physicians and payers,” said Philip J. Young, CEO of Osteologix. “In addition, our recently expanded global patent estate will allow our shareholders a long window of opportunity to realize returns on their investments.”
Different from other drug therapies available in the U.S., NB S101 is a dual acting bone agent (DABA), designed to benefit patients by strengthening the bone in two ways. Unlike the aggressive actions of other therapies, which can sometimes lead to brittle bones after several years of therapy, strontium is a moderate anti resorptive drug that also works to enhance bone mineralization giving the patients stronger, more fracture-resistant bones. Another key advantage researchers note is that strontium therapy is an excellent choice for the significant number of women who cannot take or tolerate bisphosphonate treatment, (the largest class of drugs currently used to treat osteoporosis).